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Hematopoietic stem cell transplantation (HSCT) is a pediatric cancer treatment, but 
malnutrition and fat free mass (FFM) loss during the process induce negative outcomes.  
Tracking changes in body composition, physical activity, and handgrip strength (HGS) may 
determine the effectiveness of current nutrition and physical therapy in maintaining FFM. This 
prospective quality improvement study of 9 participants receiving first-time HSCT considered 
bioelectrical impedance analysis (BIA) and HGS data at intake and discharge with nutrition, 
physical activity, medication administration, and incidence of graft versus host disease (GVHD) 
throughout admission. An overall loss of weight, FFM, and right and left HGS (p=0.009; 
p=0.020) and increased fat mass and body fat percentage were observed. Most participants 
discharged with worsened nutrition diagnoses.  No participant experienced GVHD.  No 
relationships were found between participant characteristics, steroid administration, appetite 
stimulant administration, or nutrition route. A small sample set precluded conclusive 
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Cancer affects nearly 10,500 children younger than age 15 and over 5,300 adolescents 
aged 15 to 19 each year,
1
 and is the top disease-related killer of children below the age of 15.
2
 
Hematopoietic stem cell transplant (HSCT) is a viable treatment option for pediatric cancers and 
can be performed as an autologous transplant or an allogeneic transplant. The former describes a 
technique in which bone marrow is harvested from and returned to a patient after the patient is 
treated with radiotherapy or chemotherapy or both.  The latter is a technique by which a patient 
receives marrow from a donor; this option is complicated by the challenge of finding 
histocompatibility of the HLA-genotype between donor and patient.
3
  
Proper nutrition is a significant concern for children and adolescents undergoing HSCT.  
Suboptimal nutrition status may or may not exist before transplant, but nutrition status is 
negatively impacted by several procedure-related factors during the entire transplant admission, 
such as graft-versus-host disease (GVHD), a complication that may occur in allogeneic 
transplant patients and can cause severe gastrointestinal disturbances.
3,4
  Increased metabolic 
needs due to stress, increased muscle catabolism, decreased nutrient intake, and the effects of 
cancer-associated therapy often lead to malnutrition and can impair normal growth and 
development in these children and adolescents.
4-6
  Many of the aforementioned factors also 
compromise physical functioning and result in declines in fat free mass after transplant; however, 
physical therapy regimen help maintain muscle strength.
7
  
Malnutrition, which can occur in underweight populations as well as overweight and 
obese populations, has been found to adversely affect disease outcome,
4
 lead to longer hospital 
stays,
8









Pretransplant body composition and weight change during the transplant inpatient period are also 
factors to consider, as relapse rate and risk of mortality, among other outcomes, have been 
associated with individuals of unhealthy weight, including underweight, overweight, and obese 
individuals.
10-13
  An effective and efficient tool that accurately evaluates nutrition status and 
body composition during the transplant process would help identify risk factors and direct the 
provision of adequate nutrition.   
Although several tools for assessing body composition exist, the validity of their use has 
not been confirmed in healthy populations and even less focus has been given to studying the use 
of these tools in unhealthy populations.  The sensitivity of body mass index (BMI) to low lean 
body mass is controversial and dual x-ray absorptiometry (DEXA) is expensive.
14,15
 Bioelectrical 
impedance analysis (BIA) is a less expensive and less time-consuming tool that provides more 
sensitivity to changes in body composition after HSCT than changes in body mass as measured 
by BMI.
16
  Handgrip strength (HGS) assessed by handgrip dynamometry effectively identifies 
changes in physical function
7
 and is a strong predictor of morbidity and mortality in health-
compromised individuals.
17-20
  Assessing body composition may help prevent nutrient deficits 
during the transplant process and promote advances in nutrition therapy for children and 
adolescents undergoing HSCT.   
The primary aim of this quality improvement (QI) study was to determine if current 
nutrition and physical therapy interventions are effective in maintaining fat free mass (FFM) and 
muscle strength during a child’s or adolescent’s first HSCT admission.  This was done by 
looking at the relationship between changes in FFM and HGS in relation to the nutrition 
diagnosis, dose and type of corticosteroids and appetite stimulants administered, and acute 





Pediatric cancers devastate families across the nation and around the world.  Fortunately, 
science and technology have found ways to combat these diseases and drastically reduce the 
number of deaths from childhood and adolescent cancers that occur each year.  Hematopoietic 
stem cell transplantation (HSCT) is a viable treatment modality for several of these cancers.  
Since body composition and nutritional status are highly related to cancer and the associated 
treatments, several tools have been created, tested, and analyzed to find the most effective and 
accurate technique of assessing body composition and nutrition.  It is critical to track changes in 
body composition and nutrition both before and after HSCT, as this can have significant 
implications on treatment outcome and survival.   
Prevalence of Childhood and Adolescent Cancer 
Nearly 10,500 children younger than age 15 and over 5,300 adolescents aged 15 to 19 are 
diagnosed with cancer yearly.
1,21
  Although pediatric cancer is rare, it is the top disease-related 
killer of children 14 years of age and younger.
2
  The most common cancers afflicting these 
children are acute lymphoblastic leukemia, central nervous system cancers, neuroblastoma, and 
Non-Hodgkin’s lymphoma, whereas adolescents tend to experience Hodgkin’s disease, central 
nervous system cancers, and germ cell tumors.  The latter also have higher rates of melanoma, 
thyroid cancer, non-rhabdomyosarcoma soft tissue sarcoma, osteosarcoma, and Ewing’s sarcoma 
compared to children younger than 15 years of age.
2
 Pediatric cancers of all ages are often 
treated with hematopoietic stem cell transplantation, which is subdivided into allogeneic and 




Allogeneic Bone Marrow Transplantation 
During allogeneic HSCT, a patient receives marrow from a donor.  The 
histocompatibility of the human leukocyte antigen (HLA)-genotype is an extremely important 
factor to consider when choosing a donor.
3,4
 Only about 30% of patients find such a match from 
a sibling.
22
  In an effort to create the most accepting environment for the new marrow, a patient 
matched with a donor must first receive intense doses of radiotherapy or chemotherapy or both; 
this destroys cancer cells and immunologically active cells in the host.
22
  It is crucial that the 
conditioning regimen is strong enough to induce immunosuppression of the recipient so as to 
inhibit rejection of the graft without reaching a toxic level.
3
   
Because a donor’s marrow has no malignant cells, the possibility that a graft might 
provide anticancer benefits by attacking a recipient’s cancerous cells, via the graft versus tumor 
effect, is a significant advantage of allogeneic HSCT.
22
  However, when immunocompetent graft 
cells instead attack cell antigens of the recipient after an allogeneic transplant, the resulting 
complication known as graft-versus-host disease (GVHD) has a variety of harmful 
consequences; physical manifestations most commonly appear in the skin, gastrointestinal tract, 
liver, and lungs.
3,23
  GVHD can be deadly in the most severe of cases
22
 and, in fact, is the leading 
cause of death unrelated to the original cancer diagnosis in HSCT recipients.
24
   
Autologous Bone Marrow Transplantation 
Autologous HSCT involves returning to a patient marrow that was originally harvested 
from the patient in an attempt to regenerate normal cell function after having been treated with 
intensive chemotherapy.
3,22
  Patients receiving autologous HSCT need not rely on a donor match; 
their own marrow is readily available.  Benefits of this procedure are lower costs and decreased 
rates of morbidity and mortality.
23,25,26
  The disadvantage of autologous HSCT is the possibility 
5 
 
that tumor cells may still exist within a treated graft and without the potential for a therapeutic 
donor graft versus tumor effect, the risk of relapse is much higher than with allogeneic 
HSCT.
25,26
  Nutrition is of utmost concern for any form of stem cell transplantation, as it may 
significantly impact disease outcome.   
Malnutrition 
Cancer alters metabolism and body composition in complex ways not yet fully 
understood.  Proper nutrition is crucial during times of intense stress on the body, but it is often 
very difficult for cancer patients to consume and utilize the nutrition they so desperately need 
due to a plethora of complications.
4
  This is an especially significant concern in the pediatric 
oncology population because children and adolescents need to meet nutrition requirements in 
order to achieve proper growth and development.
4
 Oral nutritional intake is lowest during the 
week immediately following transplant
27
 and appears to correlate with the occurrence of severe 
GVHD in those receiving allogeneic HSCT.
28
  Malnutrition is a major complication of cancer 
treatment associated with several adverse outcomes,
4
 including a reduction in body mass,
29
 
increased length of hospitalization,
30
 compromised quality of life,
9




Fortunately, patients are generally not afflicted with malnutrition during the pre-HSCT 
stage.
8,15
  Nutritional status upon admission does not appear to correlate with survival, mortality, 
or engraftment, but the proper metabolism of chemotherapeutic treatments may be compromised 
by poor nutrition.
32
  Likewise, conditioning regimens exacerbate nutrition concerns because they 
often cause patients to develop an array of complications such as oroesophageal mucositis, 
gastrointestinal toxicity, febrile neutropenia, nausea, vomiting, diarrhea or constipation, changes 
in taste and smell, decreased oral intake, and decreased nutrient absorption.
4,6,22,27,32,33
  As a 
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result of the nutrient depletion that occurs with cancer, patients are more susceptible to 
infections, which in turn facilitates further catabolism and increased energy needs that may 
progress to malnutrition without appropriate care.
11
   
The relatively immediate manifestations of cancer are not the only concern; pediatric 
cancer survivors have an increased risk of developing diabetes mellitus and cardiovascular 
diseases, which can progress to a lifelong diagnosis of metabolic syndrome.
34
 Because 
malnutrition can have both short- and long-term implication on cancer outcome and survival, it is 
critical that an understanding of nutrition and body composition is applied to the treatment of 
childhood and adolescent cancer.
35,36
  However, limited data in the pediatric HSCT population 
exists regarding the impact of nutrition on cancer outcome, implying a need for further studies in 
this area. 
The Implications of Low Body Mass Index and Fat Free Mass 
The loss of body mass, particularly fat free mass - which includes all body materials 
except fat - may have significant implications on cancer outcome.  Steroid therapy causes losses 
in fat free body mass, which includes both muscle and bone.
15,37
  Several consequences have 
been associated with low BMI.  As fat free body mass decreases, instances of febrile 
neutropenia, mucositis, cardiotoxicity, emesis, and hyperglycemia increase.
32
  Individuals with 
low body weight are more susceptible to infections and septicemia.
10,11
   It is possible that 
patients who are underweight are at more risk of drug toxicity as a result of overdose.
11,12
  While 
Campos and colleagues
8
 did not find a correlation between GVHD and weight loss, others have 
found that patients with low fat free body mass, when measured by dual x-ray absorptiometry 
(DXA), were at a higher risk of developing chronic GVHD, independent of body fat.
15,31
 Losses 





Underweight pediatric cancer patients experience lower survival rates
 
but in fact, the same 
consequence has been observed for overweight and obese pediatric patients.
10,12,13
  
The Implications of Overweight and Obesity 
Just as obesity is a concern in the general public, it is a concern for HSCT patients with 
even more consequences.
14
 Overweight patients may not receive enough treatment since their 
doses are calculated using adjusted or ideal body weight.
11,38
  Overweight and obese patients are 
also at higher risk of acquiring certain infections compared to normal weight patients during 
early treatment.
10
    
Research does not agree about the implications of overweight and obesity on HSCT 
outcomes.  In the adult population, obese patients may be more likely to suffer relapse than non-
obese patients and also may have a higher mortality rate.
39
  The risk for treatment-related toxicity 
seems to be higher in obese individuals than those who are non-obese.
40
  Lower overall survival 
rates are correlated with overweight and obesity in children and adolescents with leukemia.
10,12,41
   
These findings are contradicted by studies showing a lack of connection between BMI 
and nutrition status or time to engraftment and in fact support a higher likelihood of survival for 
obese patients compared to patients of normal or underweight.
42
  To further compound the 
complexity of the issue, it may be that obesity does not have the same negative effects on HSCT 
outcome in the pediatric population when compared to adult cancer patients.
39
  This is an area 
that would benefit from further research because the implications of body composition and 
nutritional status can extend far into the future. 
Body Weight in the Long Term 
The implications of cancer, cancer-related treatment, nutrition, and physical activity 
habits after discharge may have lasting effects on the health of a patient.  In many patients, 
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weight and fat free body mass remain severely below normal levels for months after 
transplant.
8,31
  Conversely, it may be that survival after HSCT predisposes an individual to 
obesity later in life.
14
 Kyle and colleagues
15
 found instances of overweight in 15% of patients six 
months after transplant, reaching a rate of 50% of patients after six years.   
The achievement of adequate nutrition and a healthy body weight is critical for quality of 
life; children with weight loss are likely to experience muscle weakness and compromised 
performance in social situations and children with weight gain are more likely to experience 
emotional and cognitive struggles.
9
  Although childhood cancer survivors are at an increased risk 
of developing components of metabolic syndrome, the insulin resistance and central obesity 
related to this condition are two factors whose courses could be influenced during and long after 
the HSCT process with appropriate monitoring and interventions.
43
  In order to accurately 
evaluate the nutritional status and body composition of patients, it is critical that an effective, 
efficient, and readily accessible tool be validated.   
Body Mass Index as a Tool for Measurement   
Body mass index has long been a tool for anthropometric assessment of the body due to 
its simple calculation and ease of access.  However, its sensitivity to both healthy and cancer-
stricken populations has been questioned.
44-46
 Low fat free mass and excess fat is not detected 
well by BMI and this flaw is emphasized when compared to precise measurements obtained by a 
DEXA, the gold standard in body composition assessment.
14,15
 BMI is a significantly flawed 
screening tool and cannot therefore be effective in accurately identifying nutritional status.
47
  
Despite the poor quality of BMI, the parameter has been investigated for its correlation to 
HSCT outcomes.  Certain studies have not identified correlations between BMI and pretransplant 
nutritional status, mortality, fat free muscle mass, or fat mass.
24,48
  These findings are supported 
9 
 
by other studies that refute the correlation between low BMI and poor survival, identifying no 
association between poor body composition and disease duration, disease remission, or the 
reduction of components of fat free mass, such as bone matter, as seen in sarcopenia.
49,50
  
Others have contradicted these findings by showing that BMI was, in fact, correlated with 
time to engraftment and survival;
51
 specifically that a BMI greater than 25, before 
transplantation, was indicative of better chances of survival and those with a low BMI.
11
  In light 
of these results, a tool that can more accurately qualify nutrition status of pediatric cancer 
patients would have significant implications on treatments and interventions.   
Bioelectrical Impedance Analysis as a Prognostic Tool 
The increased need for a more efficient, accurate, inexpensive, and non-invasive 
technique has given rise to studies evaluating the validity of bioelectrical impedance analysis 
(BIA).
52
 BIA provides information about cell membrane properties and body water distribution 
by measuring the resistance (R) and reactance (Xc) of an electrical current that is sent through a 
body.
53,54
  The relationship between R and Xc is known as phase angle (PA).  Positive PA values 
are associated with healthy individuals, whereas low or negative PA values may be indicative of 
compromised membrane permeability, cell death, losses in muscle mass, displaced body water, 
or any combination of these characteristics.
49,53,55
  PA was also found to positively correlate with 
nutrition status.
56
  Since all of these attributes may be influenced by metabolic rate and nutrition, 
BIA has been considered an effective prognostic tool for the assessment of nutritional status and 
disease.
16,53,57
  Because PA values can be transformed into standardized z-scores based on sex-, 
age-, and BMI-, population-, ethnicity- and disease-specific equations, its predictive power may 
make it a more useful tool than others that currently exist.
16,49,52,58
   
10 
 
There is a significant positive correlation between BIA-derived PA, and other standard 
measurements, including triceps skinfold, arm circumference, and arm muscle circumference.
16
 
BIA-derived PA better detects the severity of malnutrition when compared to BMI and severity 
of disease when compared to the Standardized Global Assessment.
16,58
   When compared to 
DEXA, BIA accurately reports changes in body composition, over a period of time, in children 
who are either normal weight or overweight.
59
  In addition, several studies have supported the 
reliability and accuracy of BIA,
60
 such that any change in fat free mass greater than 5% can be 
detected, and there is little disagreement between measured and calculated values for BIA.
61
   
Patients with low PA more often experience compromised nutrition and functional status, 
longer hospital stays, lower quality of life, a higher risk of relapse mortality for allogeneic HSCT 
recipients,
49
 a higher risk of mortality, and shorter survival.
16,58
  BIA values, but not BMI values, 
decrease 180 days after patients receive allogeneic HSCT, indicating that BIA is sensitive to 
changes in cell structure before these changes are identified by BMI.
16
   
However, the validity of BIA is not entirely accepted; BIA may generally underestimate 
fat free mass and total body water.
54
  There have been several instances in which fat mass and fat 
free mass were not accurately reported by BIA.
60
  Further studies are necessary to strongly 
indicate or contradict the use of BIA, as current evidence is contradictory.  The combination of 
these findings and the fact that most BIA studies have focused on the adult population makes it 
imperative that a study should focus on using BIA to assess children and adolescents before and 
after HSCT for the possibility that changes in body composition and nutrition status may be 
identified.   
11 
 
Two types of BIA exist: single-frequency and multiple-frequency.  Multi-frequency BIA 
measures intracellular and extracellular fluid in addition to FFM.
57
  Because this study did not 
require the differentiation of TBW compartments, the single-frequency model was sufficient. 
Handgrip Dynamometry as a Concomitant Assessment 
Due to the controversy surrounding the validity of BIA assessment, a concomitant 
measurement can be used for comparison of fat free mass stores.  Handgrip dynamometry is an 
efficient, effective, and inexpensive tool to assess fat free body mass. Height, fat free body mass, 
and nutritional status are positively correlated with handgrip strength (HGS),
62
 whereas a 
negative relationship exists between HGS and mortality.
7
 It is desirable that all people maintain 
proper muscle function throughout their lifespan in order to perform daily activities of living; it 
is even more important that health-compromised individuals such as pediatric oncology patients 
maintain muscle function since it is a strong predictor of mortality.
18,20
  Low muscle strength, as 
assessed by handgrip dynamometry, was found to be more predictive of postoperative morbidity 
in individuals receiving surgery after gastric cancer than calculating the amount of fat free body 
mass in those individuals,
17
 and therefore has significant implications on determining the risk of 
morbidities after cancer treatments.  Using hand grip strength as an indicator of fat free body 
mass provides another means of assessing changes in body composition of pediatric oncology 








This QI project followed 9 pediatric oncology participants, including 4 females and 5 
males, who were scheduled for either allogeneic or autologous HSCT at St. Jude Children’s 
Research Hospital between 1/1/2016 and 6/30/2016. Eligible participants were between 7 and 21 
years of age. Inclusion criteria required that participants had no limb amputations, could bear 
weight equally on both feet, could hold the BIA handgrips in both hands, and could speak 
English. Participants receiving IV fluids above maintenance and those identified as having 
edema per visual examination of hands, feet, face, and body were not eligible to participate. 
Procedure 
BIA assessment and HGS assessments were performed at two time points: once within 
+/- 3 days of intake for transplant and once at discharge after marrow infusion within +/- 3 days. 
Additional factors were recorded through the entire HSCT admission. 
Measures 
Treatment Intensity. One-time classification of treatment intensity was performed at 
admission. All participants were categorized using the Intensity of Treatment Rating (ITR)-3 
from the Children’s Hospital of Philadelphia at the time of admission.
63
  
Bio Impedance Analyzer. The BC-418 Tanita® Body Composition Analyzer (Tokyo, 
Japan) was used for this procedure. This device has a reported validity, reliability, and error 
range of +/- 5% in comparison to the DEXA when measuring body composition, as reported by 
the company. The device was calibrated before each use by a Clinical Nutrition Service member 
according to manufacturer protocol. All attempts were made to test participants under ideal 
13 
 
conditions: ≥ 12 hours after vigorous exercise, ≥ 3 hours after waking, and ≥ 3 hours after a 
meal. The participant emptied their bladder and removed any jewelry before testing began. The 
team member input the appropriate information regarding the participant’s gender, body type, 
age, and height. A standard value of one kilogram was used for all participants’ clothing weight. 
The participant stood on the BC-418 Tanita® Body Composition Analyzer electrodes with bare 
feet and without bending the knees. The participant held the grips with both hands, at which time 
the impedance measure began. Once the body composition and impedance measurements were 
completed, the participant measurements were printed from the machine and body fat 
percentage, body fat mass, and FFM were recorded. Intake BIA data was compared to discharge 
BIA data to determine if change had occurred.   
Nutrition Diagnosis. Nutrition diagnosis including the problem, etiology, and signs and 
symptoms (PES) statement per the electronic Nutrition Care Process Terminology Reference 
Manual (eNCPT)
64 
from the Academy of Nutrition and Dietetics (AND) was collected from the 
registered dietitian nutritionist’s assessment at the point of intake and at the point of discharge 
for each patient. The sub-classification of malnutrition was diagnosed using the Academy of 
Nutrition and Dietetics (AND) and the American Society for Parenteral and Enteral Nutrition 
(ASPEN) guidelines.  The primary indicators for malnutrition are listed in Table 1. 
Table 1. Indicators of Malnutrition  
 





-1 to -1.9  -2 to -2.9 -3 or greater 
BMI-for-age z-score -1 to -1.9  -2 to -2.9 -3 or greater 
Length/height-for-age 
z-score 
No data No data No data 
14 
 
Table 1. Indicators of Malnutrition  
 
 Mild Malnutrition Moderate 
Malnutrition 
Severe Malnutrition 
Weight gain velocity Less than 75% of the 
norm for expected 
weight gain 
Less than 50% of the 
norm for expected 
weight gain 
Less than 25% of the 
norm for expected 
weight gain 
Weight loss 5% usual body weight 7.5% usual body 
weight 





Decline of 1 z-score Decline of 2 z-scores Decline of 3 z-scores 
Becker P, Carney LN, Corkins MR, Monczka J, Smith E, Smith SE, Spear BA, White JV, 
Academy of Nutrition and Dietetics, American Society for Parenteral and Enteral Nutrition 
(2015). Consensus statement of the Academy of Nutrition and Dietetics/American Society for 
Parenteral and Enteral Nutrition: indicators recommended for the identification and 
documentation of pediatric malnutrition (undernutrition). Nutr Clin Pract. 2015;30(1):147-161 
 
Handgrip Strength Assessment. HGS in kilograms was assessed by an inpatient physical 
therapist (PT), using a Jamar Hydraulic Hand Dynamometer (Patterson Medical, Atlanta, GA), at 
the point of intake and discharge. Strength data was compared to HGS norms for ages 6-19 
(B&L Engineering, 1986).  Participants were seated with the shoulder at 0-10° and the elbow in 
90° of flexion. The forearm was in neutral position. Each participant completed three trials and 
the average was used for analysis.
65,66   
Strength at intake was compared to strength at discharge 
to determine if change had occurred.   
Nutrition Intake and Requirements. Averages of kilocalorie and protein intake including 
parenteral and enteral routes were obtained during the entire HSCT admission and expressed as 
an overall percentage of estimated needs: percentage of kilocalorie needs met (PKNM) and 
percentage of protein needs met (PPNM).  Oral nutrition intake was analyzed using Nutritionist 
Pro software v. 6.2 (Axxya Systems, Stafford, TN) or obtained from the calculated values in the 
nutritionist’s note.  Kilocalorie and protein intakes from total parenteral nutrition (TPN) and 
enteral nutrition (EN) routes were obtained from the metabolic infusion support service notes in 
15 
 
the electronic medical records. Estimated energy requirements were calculated using the World 
Health Organization (WHO) equation with a factor of 1.2 to 1.4 to determine total kilocalorie 
requirements. Protein requirements were calculated using a 200-total kilocalorie: nitrogen ratio.  
PKNM and PPNM were compared to changes in FFM and HGS measured from time of intake to 
time of discharge.   
Symptoms. Acute GVHD was diagnosed, staged, and graded according to the COG Stem 
Cell Committee Consensus Guidelines for Establishing Organ Stage and Overall Grade of Acute 
GVHD, Appendix 4 BMTCT SOP.
67
  Duration and stage of aGVHD was recorded and evaluated 
for comparison to changes in FFM and strength. Nutrition-related adverse events rated greater 
than 3, according to the Common Terminology Criteria for Adverse Events (CTCAE) per the 
National Institutes of Health (NIH) and National Cancer Institute (NCI), were collected if the 
conditions presented.
68
  The nutrition-related adverse events that were recorded include: 
diarrhea, malabsorption, mucositis, nausea, vomiting, and anorexia. The type of adverse event 
and total number of days present were evaluated for comparison with changes in FFM and HGS.   
Medication Dosage. Corticosteroid administration was obtained from the medical record.  
Type, cumulative dose, indication for usage, and total number of days provided were recorded 
and compared with changes in FFM and HGS.  In addition, type, average dose of appetite 
stimulant, and total number of days provided were recorded and compared with changes in FFM 
and HGS.   
Physical Activity Duration. Duration of physical activity, in minutes, was collected from 
the PT note as well as from self-report of activity by the participant and/or the family of the 
participant. Average time spent doing physical activity was analyzed for comparison to changes 
in FFM and HGS. 
16 
 
Data Analysis and Statistics 
This was a quality improvement project with an aim to determine if current nutrition and 
physical therapy interventions were effective in maintaining FFM and muscle strength during the 
initial HSCT admission. We enrolled 9 patients for either allogeneic or autologous HSCT. 
  To determine if current nutrition and physical therapy interventions are effective in 
maintaining FFM and HGS during the initial admission. We evaluated the kilocalories and 
protein as an overall percentage of estimated needs and the average number of minutes spent 
doing physical activity from the time of intake to the time of discharge. The paired one-sample t-
test or Wilcoxon signed rank test was used to test if there was significant difference in change in 
FFM and HGS, from intake to discharge, depending on the normality of the data tested by 
Shapiro-Wilk test.  The SAS 9.4 software package was used for the statistical analysis. A p-value 
of 0.05 was considered significant. Summary statistics including mean, standard deviation, 
median and range for continuous variables and the number and percentage for categorical 
variables are provided. 
To explore the relationship between changes in FFM and HGS based on cumulative 
steroid dose, appetite stimulant type, duration and grade of aGVHD. Descriptive and raw data 







Characteristics of the Participants 
A total of 9 pediatric oncology participants scheduled to receive their first of either an 
allogeneic (66.6%) or autologous (33.3%) HSCT were included in the study (Table 2).  
Allogeneic HSCT were either haploidentical (n=3), matched-sibling donor (n=1), or matched-
unrelated donor (n=2) transplants. The majority of participants (55.6%) were male and their 
median age was 15 years (8-19). The diagnoses of the participants that precipitated a need for 
HSCT included acute leukemia (33.3%), Hodgkin’s lymphoma (33.3%), and solid tumor 
malignancies (33.3%). The majority of the participants were white (66.7%). All participants met 
the criteria for level 4 of the ITR-3 rating system; therefore this data is not presented in a table. 
Table 2. Characteristics of the participants at intake.  
 
Characteristics Number (n = 0) 
Sex female (%) 4 (44.4) 
 
male (%) 5 (55.6) 
Median age (range) 
 
15 (8-19) 
Diagnosis Acute Leukemia 3 (33.3) 
 
Hodgkin's 
Lymphoma 3 (33.3) 
 
Solid Tumors 3 (33.3) 
Race Asian 1 (11.1) 
 
Black 1 (11.1) 
 
Other 1 (11.1) 
 
White 6 (66.7) 
Type of Transplant Allo (Haplo) 3 (33.3) 
 
Allo (MSD) 1 (11.1) 
 
Allo (MUD) 2 (22.2) 
  Auto 3 (33.3) 






Nutrition Diagnosis at Intake and Discharge 
Six participants were diagnosed with predicted suboptimal nutrient intake; of those, only 
two improved by discharge as evidenced by receiving no nutrition diagnosis (Table 3). The only 
other participant that improved to no nutrition diagnosis by discharge had been admitted with a 
nutrition diagnosis of inadequate oral intake. Three participants were discharged with inadequate 
oral intake and one was diagnosed with mild malnutrition; this last participant was the youngest 
and had been admitted with a diagnosis of predicted suboptimal intake, indicating significant 
nutrient depletion had occurred during HSCT admission. No other trend was observed between 
type of transplant, age, or nutrition diagnoses for either intake or discharge.   
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Table 3. Nutrition diagnosis (PES statement) of the participants at intake and discharge related to age, sex, and type of transplant  
 
 
P Age Sex 
Transplant 
Type Intake PES statement Discharge PES statement 
1 15 F Allo (MSD) Predicted suboptimal nutrient intake related to planned allogenic 
HSCT (MSD) per NPTP protocol as evidenced by history of 
marginal/suboptimal energy intake. 
No nutritional diagnosis at this time. 
2 15 M Allo (Haplo) Altered nutrition-related laboratory values related to cancer directed 
therapy/endocrine dysfunction as evidenced by low vitamin D level. 
Inadequate oral intake and swallowing difficulty related to 
inability to consume sufficient energy as evidenced by sore 
throat, inability to swallow food/pills, and nasogastric tube 
(NGT) for medications.  
3 15 M Allo (Haplo) Inadequate oral intake related to decreased ability to consume 
sufficient energy as evidenced by 6% or 3 kg weight loss over past 4 
months but stable over past month; need for oral supplementation 
with Boost nutritional drink.  
Inadequate oral intake related to decreased ability to consume 
sufficient energy as evidenced by sore throat, diet history, and 
recent weight loss since discharge. 
4 8 M Auto Predicted suboptimal nutrient intake related to inability to consume 
sufficient energy as evidenced by history of suboptimal energy 
intake, upcoming HSCT. 
Malnutrition (mild) related to decreased ability to consume 
sufficient energy as evidenced by BMI for age Z score of -1.81 
but PO intake improving. 
5 19 F Allo (MUD) Predicted suboptimal nutrient intake related to planned allogenic 
HSCT (MUD) as evidenced by previous history of 
marginal/suboptimal energy intake. 
Inadequate oral intake related to decreased ability to consume 
sufficient energy as evidenced by diet history; met only 31% of 
estimated needs with PO intake yesterday and continued need for 
parenteral nutrition (PN). 
6 12 F Auto Predicted suboptimal nutrient intake related to planned autologous 
HSCT therapy as evidenced by previous history of suboptimal 
energy intake. 
Inadequate oral intake related to decreased ability to consume 
sufficient energy as evidenced by diet history and need for 
continuous nasogastric tube (NGT) feeds. 
7 13 F Allo (MUD) Predicted suboptimal nutrient intake related to upcoming HSCT as 
evidenced by known side effects. 
No nutritional diagnosis at this time. 
8 13 M Auto Inadequate oral intake related to decreased ability to consume 
sufficient energy due to relapsed Hodgkin's Lymphoma as evidenced 
by poor PO intake, need for oral supplement, and 9.2% weight loss 
over past 20 days (9.1kg).  
No nutritional diagnosis at this time. 
9 17 M Allo (Haplo) Predicted suboptimal nutrient intake related to upcoming HSCT as 
evidenced by known side effects. 
Inadequate oral intake related to decreased ability to consume 
sufficient energy as evidenced by diet history resulting in a 6.4% 
or 3.4% weight loss over the past month. 
P, participant; PES, problem, etiology, signs and symptoms; Allo, allogenic; MSD, matched sibling donor; Haplo, haploidentical; Auto, autologous; MUD, 
matched unrelated donor. 
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Changes in Body Measurements 
Due to a small sample size, no significant p-values were identified after statistical 
analysis with the exception of those related to HGS; however, several insignificant trends in the 
data were observed. During HSCT admission, more participants lost weight (n=5) than gained 
weight (n=4).  Overall, there an average weight loss of 0.4 kilogram.  The majority of 
participants lost FFM (n=5) as well as FM (n=5).  While there was an average FFM loss of 0.4 
kilogram, there was an average gain of 0.1 kilogram of FM during HSCT admission. Body fat 
percent was increased in the majority of the participants (n=5) and the average overall body fat 
percent gain was 0.1%. All but one participant lost HGS on both right and left sides; one 
participant gained muscle strength, as assessed by right upper extremity (RUE) HGS, and a 
different participant gained muscle strength, as assessed by left upper extremity (LUE) HGS. An 
average of 3.1 kilograms worth of strength were lost on the right side (p=0.009) and 2.4 
kilograms of strength were lost on the left side (p=0.020) (Table 4). No relationships were 
observed between age or type of transplant with magnitude of change in FFM, FM, body fat 
percent, or grip strength.
21 
 
Table 4. Changes in body measurements of the participants from intake to discharge. 
 
  Transplant 
Type 
Weight (kg) Fat Free Mass (kg) Fat Mass (kg) % Body Fat HGS RUE (kg) HGS LUE (kg) 
P In Dc CHG In Dc CHG In DC CHG In Dc CHG In Dc CHG In Dc CHG 
1 Allo (MSD) 43.4 43.6 0.2 32.9 31.9 -1.0 10.5 11.7 1.2 24.2 26.8 2.6 14.2 11.3 -2.9 10.3 9.0 -1.3 
2 Allo (Haplo) 60.8 63.3 2.5 52.0 53.5 1.5 8.8 9.8 1.0 14.5 15.5 1.0 29.0 22.7 -6.3 22.6 17.7 -4.9 
4 Allo (Haplo) 47.1 44.0 -3.1 40.1 37.3 -2.8 7.0 6.7 -0.3 14.9 15.3 0.4 19.9 20.4 0.5 17.2 17.0 -0.2 
4 Auto 22.2 21.5 -0.7 18.7 18.8 0.1 3.5 2.7 -0.8 15.8 12.4 -3.4 10.3 10 -0.3 10.0 8.3 -1.7 
5 Allo (MUD) 59.3 60.2 0.9 39.1 42.0 2.9 20.2 18.2 -2.0 34.0 30.3 -3.7 18.7 13 -5.7 14.7 10.4 -4.3 
6 Auto 35.4 35.9 0.5 28.5 27.8 -0.7 6.9 8.1 1.2 19.5 22.6 3.1 11.7 10.6 -1.1 4.7 4.3 -0.4 
7 Allo (MUD) 46.4 45.6 -0.8 35.6 36.0 0.4 9.7 9.6 -0.1 21.5 21.1 -0.4 20.0 17.3 -2.7 18.6 13.7 -4.9 
8 Auto 91.0 90.9 -0.1 63.1 61.4 -1.7 27.9 29.5 1.6 30.7 32.5 1.8 29.0 26.7 -2.3 24.0 25.3 1.3 
9 Allo (Haplo) 67.5 64.5 -3.0 55.3 53.2 -2.1 12.2 11.3 -0.9 18.1 17.5 -0.6 41.3 34.0 -7.3 34.0 28.7 -5.3 











Median (Range) -0.1(-3.1~2.5) -0.7(-2.8~2.9) -0.1(-2.0~1.6) 0.4(-3.7~3.1) -2.7 (-7.3~0.5) -1.7 (-5.3~1.3) 
P-Value   0.52     0.54     0.81     0.91     0.009     0.02 
P, participant; In, intake; Dc, discharge; CHG, change; kg, kilograms; Allo, allogenic; MSD, matched sibling donor; Haplo, haploidentical; Auto, autologous; 
MUD, matched unrelated donor; HGS, hand grip strength; RUE, right upper extremity; LUE, left upper extremity.
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Factors Impacting Nutrition Status 
Nutrition supportive techniques were used in four of the nine participants, two of which 
required only EN; the other two required both EN and TPN. None (n=0) of the participants 
consumed enough nutrition by any route during HSCT admission to meet their estimated energy 
or protein needs (Table 5). No relationships were observed between route of nutrition with 
magnitude of change in FFM, FM, body fat percent, or grip strength. 
The majority (n=6) of participants received steroids at some point during HSCT 
admission. The most common types, hydrocortisone and methylprednisolone, were most often 
administered in preparation for protocol-specific therapy. Other indications included 
Engraftment Syndrome, preparation for blood transfusion, and allergic drug reaction. Most (n=5) 
of the participants also received appetite stimulants at some point during their HSCT admission.  
Dronabinol was most commonly used, but one participant received cyproheptadine. Not all 
participants who received steroids also received appetite stimulants; the opposite is true as well.  
Participants who did not receive steroids (n=3) saw an increase in weight, fat mass, and percent 
body fat along with a loss in muscle strength on both right and left sides. Participants who 
received appetite stimulants (n=5) lost muscle strength with the exception of one participant, 
who gained strength on the left side. Participants 1, 8, and 9 had the least amount of physical 
activity per day, all of whom (n=3) lost FFM and generally lost muscle strength.  Only one 
participant self-reported minutes of physical activity; therefore, only physical activity as reported 




Table 5. Variables affecting nutrition status of the participants during the transplant admission. 
 





























































































    
1 Allo (MSD) 23 PO 61 61  95 95  0 0 None   3 13 Dronabinol 6.52 No 
2 Allo (Haplo) 32 PO 6 72  7 82  0 0 None   0 0 None 10.28 No 
EN 1  1   
TPN 65  74   
3 Allo (Haplo) 31 PO 52 69  77 94  4 600 Hydrocortisone Pre-med for Alemtuzumab  0 0 None 16.84 No 
EN 17  17   
4 Auto 21 PO 54 54  67 67  1 30 Hydrocortisone Pre-med for blood transfusion  3 15 Dronabinol 13.24 N/A 
5 Allo (MUD) 32 PO 23 62  20 81  8 1795 Hydrocortisone Pre-med for Thymoglobulin 
(1200mg); Engraftment 
Syndrome (595mg) 
 4 10 Cypro-
heptadine 
11.91 No 
EN 6  8  4 500 Methyl-
prednisolone 
Pre-med for Thymoglobulin  
TPN 34  53   
6 Auto 22 PO 45 53  44 51  0 0 None   0 0 None 13.64 N/A 
EN 7  7   
7 Allo (MUD) 30 PO 79 79  75 75  3 699 Hydrocortisone Pre-med for Thymoglobulin  29 285 Dronabinol 14.77 No 
  3 279 Methyl-
prednisolone 
Pre-med for Thymoglobulin  
8 Auto 20 PO 71 71  53 53  6 550 Hydrocortisone Allergic drug reaction  6 30 Dronabinol 8.50 N/A 
9 Allo (Haplo) 28 PO 55 55   76 76   5 545 Hydrocortisone Engraftment Syndrome   0 0 None 8.39 No 
LOS, length of stay; PKNM, percentage of kilocalorie needs met; PPNM, percentage of protein needs met; RS, route-specific; AS, appetite stimulant; PA, 







This is the first study to consider the impact of nutrition intake, physical therapy, steroid 
administration, appetite stimulant administration, and incidence of GVHD on changes in body 
mass assessed by BIA and HGS during the initial HSCT admission to treat pediatric cancer. 
While the small sample size precluded the identification of significance except for changes in 
HGS, the participants in this study appeared to experience an overall, but insignificant, fat mass 
increase, body fat percentage increase, and weight loss. FFM loss was reflected by a significant 
decrease in HGS.   
Nutrition Diagnosis at Intake and Discharge 
Nutrition is essential in the pediatric population for its role in growth and development
4
 
and particularly significant when affected by cancer. In this study, the majority of participants at 
intake received a nutrition diagnosis predictive of suboptimal nutrient intake. The remaining 
participants were diagnosed with pre-existing poor nutrition status; similar results were reported 
by White and colleagues,
35
 who suggested that many children already have suboptimal nutrition 
even before undergoing HSCT.   
While pre-HSCT nutrition status may not influence survival,
32
 any decline in nutrition 
status during HSCT admission can compromise recovery.
69
  Low oral intake and compromised 
gastrointestinal dysfunction are expected due to disease- and treatment-related side 
effects,
4,6,22,27,32,33
 rendering a patient unable to meet nutrient requirements.
69
  Nutrient depletion 
predisposes patients to infections,
10
 increased catabolism, and risk of malnutrition.
11
   
Suboptimal nutrition during the course of cancer and treatment
70
 has significant implications on 





Changes in Body Measurements 
The change in body mass during HSCT is a phenomenon that demands attention.  The 
majority of the participants in this study lost weight during HSCT and of those, most also 
experienced a loss of fat free mass accompanied by a reduction in HGS. Similar losses in lean 
mass were reported by Inaba and colleagues,
31
 after a longitudinal study at St. Jude Children’s 
Research Hospital that followed 179 cancer survivors who received HSCT. While lean mass 
stores were considerably lower in these individuals, fat mass stores were maintained. 
Medications like glucocorticoids and appetite stimulants can raise body adiposity,
72
 but do not 
have a positive effect on fat free mass.  A study by den Hoed et al
73
 showed that weight loss 
during pediatric cancer treatment is characterized mostly by lean mass loss, which has been 
associated with hyperglycemia, cardiotoxicity,
32
 relapse, and decreased survival;
73
 therefore 




 BMI has long been used for anthropometric assessment, but its sensitivity to both healthy 
and cancer-stricken populations is questioned,
44-46
 prompting a need for a more effective marker 
of health status.  In this study, we measured HGS as a concomitant measurement to BIA data 
because reductions in HGS have been associated with loss of lean and fat mass.
19
 Several studies 
have also suggested that HGS is independently and positively associated with nutrition status, 
aside from body mass data.
62,75,76
  Despite the small sample size of this study, HGS 
measurements indicate the participants experienced a significant loss of muscle strength, and 





Factors Impacting Nutrition Status 
It was not possible to identify associations between nutrition support and changes in body 
composition in this study. Baumgartner and colleagues
74
 reported that engraftment occurs more 
quickly in children who receive parenteral nutrition after undergoing HSCT.  Nutrition support 




  As mentioned previously, malnutrition has been associated with length of stay. However, 
in this study it was observed that participants with the shortest lengths of stay also had some of 
the lowest percent-needs-met; one such participant was ultimately diagnosed with mild 
malnutrition at discharge.  Unlike those with short lengths of stay that tended to consume 
nutrition only orally, the majority of those with the longest lengths of stay received nutrition 
support in some form. Nutrition support can prolong a hospital admission due to the need for 
monitoring and the requirement to achieve a baseline status before receiving approval for 
discharge from the hospital.  This is corroborated by Espinoza and colleagues,
77
 who found that 
TPN was correlated with length of stay in patients receiving HSCT.  Of note, those who received 
nutrition support in this study also had some of the highest PPNM and PKNM, suggesting that 
despite longer hospital stays, better nutrition status may be achieved through the artificial 
provision of nutrients.  Murphy and colleagues
36
 have also suggested that nutrition support be 
employed as a means to achieve better short- and long-terms outcomes in childhood cancer.  
Limited data in the pediatric HSCT population exists regarding nutrition status during HSCT 
admission and the impact of nutrition on cancer outcome, demonstrating a need for continued 
studies in this area. 
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 Limitations of this study include a small sample size that prevented the finding of 
significant data, with the exception of HGS.  Measurement error was also an issue; any trends in 
weight and body mass could be falsely interpreted because the changes recorded in the data are 
not large enough to overcome the percent error of the BIA machine. It is impossible to know if 
the changes observed are measurement error or actual body mass fluctuations. It was also very 
difficult to capture an accurate measurement of physical activity; records of scheduled activity 
within PT notes were readily accessible on the patient database used by the institution, but the 
tool used for self-report of physical activity was neglected by all but one participant, 
demonstrating the need for a better technique to accurately report this factor.  In future studies, it 
will be pertinent not only to develop this tool, but also to include physical activity minutes 
performed while participating in occupational therapy.  A more advanced version of the BIA 
scale used in this study would permit the assessment of children younger than 7 years of age, 
thus increasing the participant pool from which data could be collected. 
Conclusion 
This study suggests that pediatric oncology patients undergoing HSCT for the first time 
may experience an overall weight loss characterized by an increase in fat mass and body fat 
percentage with a concomitant reduction in fat free mass, as evidenced by significantly decreased 
HGS.  All patients were diagnosed at intake with pre-existing suboptimal nutrition or were 
expected to become poorly nourished and most were discharged with diagnoses indicating 
continued suboptimal nutrition.  None consumed sufficient nutrients to meet their estimated 
needs for either energy or protein.  Improved identification of nutrition status and provision of 
nutrients during HSCT admission may combat negative changes in body composition and have a 
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